10-Q: Boston Scientific Q3 Earnings Soar on Strong Sales, Acquisitions

Boston Scientific reported a significant 20.3% increase in Q3 2025 net sales and a 59.4% rise in diluted EPS, driven by robust commercial execution and strategic acquisitions.

Summary

• Net sales for Q3 2025 increased by 20.3% to $5.065 billion, with operational growth of 19.4% and organic growth of 15.3% compared to Q3 2024.
• Diluted EPS for Q3 2025 was $0.51, up from $0.32 in Q3 2024. Adjusted diluted EPS was $0.75, up from $0.63.
• For the first nine months of 2025, net sales grew 21.4% to $14.788 billion, and diluted EPS was $1.49, up from $0.87 in the prior year. Adjusted diluted EPS for the nine months was $2.26, up from $1.81.
• Key growth drivers included the Electrophysiology business unit, led by the Farapulse Pulsed Field Ablation System, and the Watchman business unit, driven by the adoption of concomitant procedures in the U.S.
• The company completed several acquisitions in 2025, including Anrei Medical, SoniVie, Intera Oncology, Bolt Medical, and Cortex, and announced an agreement to acquire Nalu Medical.
• A global restructuring program (2023 Restructuring Plan) was expanded by up to $250 million in additional pre-tax charges, with total estimated charges of $700 million to $800 million, expected to be substantially complete by the end of 2025.
• Worldwide sales of the ACURATE Neo2 and ACURATE Prime Aortic Valve Systems were discontinued, resulting in approximately $90 million in inventory charges in the first nine months of 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant increases in net sales and EPS, driven by successful product launches and strategic acquisitions. While facing increased R&D costs and some inventory charges, the overall outlook is positive, supported by robust operational execution and compliance with financial covenants.

Positives

• Strong net sales growth: 20.3% for Q3 2025 ($5.065 billion) and 21.4% for the first nine months of 2025 ($14.788 billion).
• Significant increase in diluted EPS: $0.51 in Q3 2025 (up from $0.32) and $1.49 for the first nine months (up from $0.87).
• Adjusted diluted EPS also showed strong growth: $0.75 in Q3 2025 (up from $0.63) and $2.26 for the first nine months (up from $1.81).
• Robust operational (19.4% Q3, 21.0% 9M) and organic (15.3% Q3, 16.9% 9M) net sales growth, indicating strong underlying business performance.
• Electrophysiology and Watchman business units were key growth drivers, particularly the Farapulse Pulsed Field Ablation System and WATCHMAN LAAC Devices.
• Strategic acquisitions (Anrei Medical, SoniVie, Intera Oncology, Bolt Medical, Cortex) are expanding the product portfolio and market reach, with an agreement to acquire Nalu Medical.
• Increased cash and cash equivalents to $1.275 billion as of September 30, 2025, from $414 million at December 31, 2024.
• Compliance with the maximum permitted leverage ratio covenant (2.02 times actual vs. 4.75 times permitted).
• The full $1.000 billion stock repurchase program authorization remains available.
• SG&A expenses decreased as a percentage of net sales (34.4% in Q3 2025 vs 37.1% in Q3 2024).

Negatives

• Increased R&D expenses by 26% in Q3 2025 and 28% for the first nine months of 2025, impacting profitability margins.
• Inventory charges of approximately $90 million in the first nine months of 2025 due to the discontinuation of the ACURATE platform.
• Foreign currency translation adjustment resulted in a significant loss of $(719) million for the nine months ended September 30, 2025, compared to $(79) million in the prior year.
• Interest expense increased to $(87) million in Q3 2025 and $(259) million for the first nine months of 2025, due to higher average borrowing rates and outstanding debt.
• Ongoing legal proceedings and governmental investigations pose potential financial and reputational risks.

Risks

• Uncertain domestic or international economic conditions, including inflationary pressures, interest rates, monetary and tax policy, and changing trade/tariff policies.
• Disruptions in the supply of materials and components, or sterilization of products, leading to cost increases and limited availability.
• Labor shortages and increases in wage costs.
• Impact of competitive offerings, value-based procurement practices, and changes in reimbursement policies on product pricing.
• Variations in outcomes of ongoing and future clinical trials and market studies, and perceived product performance.
• Ability to acquire, develop, launch, and supply new products and technologies successfully and in a timely manner.
• Challenges in integrating acquisitions and realizing expected benefits and cost synergies.
• Enhanced requirements to obtain and maintain regulatory approval globally, including EU Medical Device Regulation (MDR) implementation costs and timing.
• Costs and risks associated with current and future asserted litigation, including patent infringement, product liability, and governmental investigations (e.g., FCPA, DOJ subpoenas).
• Potential failure to protect intellectual property rights.
• Cybersecurity events, data breaches, and other malicious actors impacting information technology and operational technology systems.
• Geopolitical events and uncertainties, including global conflicts and tensions (e.g., Russia/Ukraine war, Middle East conflicts, Taiwan strait), potentially causing disruptions and sanctions.
• Potential goodwill and intangible asset impairment charges.
• Impact of new or revised accounting standards.
• Unfavorable resolution of open tax matters and changes in U.S. and international tax laws (e.g., Pillar Two global minimum tax, OBBBA).

Future Outlook

The company anticipates continued strong commercial execution, particularly in Electrophysiology and Watchman, driving profitable sales growth. Investments in R&D will support new technologies and product pipelines. The 2023 Restructuring Plan is expected to be substantially complete by the end of 2025, aiming for operational efficiencies. The acquisition of Nalu Medical is expected to close in the first half of 2026. The economic environment remains subject to uncertainties including inflation, interest rates, trade policies, and geopolitical factors, which could impact business operations and costs. The One Big Beautiful Bill Act (OBBBA) and the OECD's Pillar Two global minimum tax framework are being monitored for their potential impact on the effective tax rate, with significant uncertainty remaining regarding their implementation and interaction with existing tax laws.

Management Comments

• Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.
• We advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare.
• We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses.
• The increase in R&D expenses in both periods was driven by investments across our businesses, including those required to support the development and clinical evidence necessary to bring newly acquired technologies to market and maintain a pipeline of products that we believe will contribute to profitable sales growth.
• We believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, service and repay our existing debt and fund possible acquisitions for the next 12 months and for the foreseeable future.
• We believe that we have the ability to comply with the financial covenant for the next 12 months.

Industry Context

Boston Scientific operates in the highly technology-driven medical device market, focusing on less-invasive medicine. The company's strong performance in Electrophysiology (Farapulse PFA System) and Left Atrial Appendage Closure (WATCHMAN devices) reflects a broader industry trend towards advanced, minimally invasive procedures. Strategic acquisitions are a common industry strategy to expand portfolios and gain market share, particularly in high-growth areas like chronic pain (Nalu Medical), gastroenterology (Anrei Medical), hypertension (SoniVie), and oncology (Intera Oncology). The industry faces ongoing challenges from global supply chain constraints, inflationary pressures, and evolving regulatory landscapes (e.g., EU MDR, global minimum tax frameworks).

Corporate Governance

Legal Proceedings

• Ongoing patent infringement lawsuit with The Board of Regents, University of Texas System and TissueGen. Inc. (UT) regarding the Synergy Stent System, with both parties having filed appeals following a jury award of $42 million in damages to UT and a subsequent court ruling of no willful infringement.
• Arbitration dispute with the Al Mann Foundation (AMF), assumed with the Axonics acquisition, concerning licensing agreements and royalties for non-rechargeable sacral neuromodulation products, scheduled for a hearing in December 2025.
• Multiple product liability cases or claims related to transvaginal surgical mesh products, predominantly in the United States, Canada, the United Kingdom, Scotland, Ireland, and Australia, with an established accrual of $306 million for remaining claims.
• Ongoing governmental investigations, including a DOJ subpoena (April 2023) related to the ambulatory electrocardiography monitoring business, a DOJ Civil Investigative Demand (December 2023) concerning peripheral intervention services through office-based labs, and an FCPA investigation in Vietnam (March 2022) with related subpoenas from the DOJ and SEC.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance, increased EPS, and the availability of a $1.000 billion stock repurchase program. Potential for future growth through strategic acquisitions.
• Employees: Impacted by the 2023 Restructuring Plan, which includes termination benefits and aims for operational efficiencies. Stock-based compensation plans continue.
• Customers: Benefit from new product launches (e.g., Farapulse PFA System, WATCHMAN LAAC Devices) and expanded product portfolios through acquisitions. Affected by the discontinuation of ACURATE Neo2 and ACURATE Prime Aortic Valve Systems.
• Creditors: Company remains in compliance with financial covenants, indicating sound debt management. Long-term debt increased due to Eurobond offerings, but current debt obligations decreased.
• Suppliers: Subject to global supply chain conditions, including potential cost increases and limited availability of raw materials. The supplier financing program allows early payment at a nominal discount.

Next Steps

• Close the acquisition of Nalu Medical, Inc. during the first half of 2026.
• Substantially complete the 2023 Restructuring Plan by the end of 2025.
• Continue phased implementation of the new global ERP system, with future phases expected to materially impact internal controls.
• Arbitration hearing for the Axonics dispute with the Al Mann Foundation scheduled for December 2025.
• Monitor and assess the impact of new accounting pronouncements (FASB ASC Updates 2023-09, 2024-03, 2025-06, 2025-07).
• Monitor future legislative developments regarding the applicability of the Pillar Two tax on U.S. companies and additional guidance by the U.S. Department of the Treasury regarding OBBBA.

Key Dates

Recommendation

Boston Scientific's Q3 2025 results demonstrate exceptional growth across key financial metrics, including a 20.3% increase in net sales and a 59.4% rise in diluted EPS. The company's strategic focus on high-growth areas like Electrophysiology and Left Atrial Appendage Closure, coupled with a robust acquisition strategy, positions it for continued market leadership. Despite ongoing industry challenges and increased R&D investments, the company's strong operational execution, healthy cash flow from operations, and compliance with financial covenants indicate a solid financial foundation and significant upside potential for investors. The remaining $1.000 billion stock repurchase authorization further signals confidence in future performance.

Keywords

Medical Devices, Boston Scientific, BSX, Q3 2025 Earnings, Acquisitions, Cardiology, MedSurg, Electrophysiology, Farapulse Pulsed Field Ablation System, WATCHMAN LAAC Devices, Neuromodulation, Peripheral Interventions, SEC Filing, 10-Q, Financial Results, Restructuring, Supply Chain, Regulatory Compliance, Patent Litigation, Product Liability